vs
Side-by-side financial comparison of Celanese Corp (CE) and BeOne Medicines Ltd. (ONC). Click either name above to swap in a different company.
Celanese Corp is the larger business by last-quarter revenue ($2.2B vs $1.5B, roughly 1.5× BeOne Medicines Ltd.). BeOne Medicines Ltd. runs the higher net margin — 4.4% vs 0.6%, a 3.8% gap on every dollar of revenue. On growth, BeOne Medicines Ltd. posted the faster year-over-year revenue change (32.8% vs -7.0%). BeOne Medicines Ltd. produced more free cash flow last quarter ($379.8M vs $168.0M). Over the past eight quarters, BeOne Medicines Ltd.'s revenue compounded faster (41.2% CAGR vs -8.1%).
Celanese Corporation, formerly known as Hoechst Celanese, is an American technology and specialty materials company headquartered in Irving, Texas. It is a Fortune 500 corporation. The company is the world's leading producer of acetic acid, producing about 1.95 million tonnes per year, representing approximately 20% of global production. Celanese is also the world's largest producer of vinyl acetate monomer (VAM).
BeOne Medicines Ltd.ONCEarnings & Financial Report
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
CE vs ONC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.2B | $1.5B |
| Net Profit | $14.0M | $66.5M |
| Gross Margin | 19.1% | 90.5% |
| Operating Margin | 4.0% | 12.4% |
| Net Margin | 0.6% | 4.4% |
| Revenue YoY | -7.0% | 32.8% |
| Net Profit YoY | 100.7% | 143.8% |
| EPS (diluted) | $0.13 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.2B | $1.5B | ||
| Q3 25 | $2.4B | $1.4B | ||
| Q2 25 | $2.5B | $1.3B | ||
| Q1 25 | $2.4B | $1.1B | ||
| Q4 24 | $2.4B | $1.1B | ||
| Q3 24 | $2.6B | $1.0B | ||
| Q2 24 | $2.7B | $929.2M | ||
| Q1 24 | $2.6B | $751.7M |
| Q4 25 | $14.0M | $66.5M | ||
| Q3 25 | $-1.4B | $124.8M | ||
| Q2 25 | $199.0M | $94.3M | ||
| Q1 25 | $-21.0M | $1.3M | ||
| Q4 24 | $-1.9B | $-151.9M | ||
| Q3 24 | $116.0M | $-121.3M | ||
| Q2 24 | $155.0M | $-120.4M | ||
| Q1 24 | $121.0M | $-251.2M |
| Q4 25 | 19.1% | 90.5% | ||
| Q3 25 | 21.5% | 86.1% | ||
| Q2 25 | 21.1% | 87.5% | ||
| Q1 25 | 19.9% | 85.2% | ||
| Q4 24 | 22.7% | 85.8% | ||
| Q3 24 | 23.5% | 83.0% | ||
| Q2 24 | 24.2% | 85.1% | ||
| Q1 24 | 21.2% | 83.4% |
| Q4 25 | 4.0% | 12.4% | ||
| Q3 25 | -52.7% | 11.5% | ||
| Q2 25 | 9.2% | 6.7% | ||
| Q1 25 | 7.0% | 1.0% | ||
| Q4 24 | -59.3% | -7.0% | ||
| Q3 24 | 9.4% | -12.0% | ||
| Q2 24 | 9.4% | -11.5% | ||
| Q1 24 | 8.0% | -34.8% |
| Q4 25 | 0.6% | 4.4% | ||
| Q3 25 | -56.1% | 8.8% | ||
| Q2 25 | 7.9% | 7.2% | ||
| Q1 25 | -0.9% | 0.1% | ||
| Q4 24 | -80.8% | -13.5% | ||
| Q3 24 | 4.4% | -12.1% | ||
| Q2 24 | 5.8% | -13.0% | ||
| Q1 24 | 4.6% | -33.4% |
| Q4 25 | $0.13 | $0.05 | ||
| Q3 25 | $-12.39 | $0.08 | ||
| Q2 25 | $1.81 | $0.06 | ||
| Q1 25 | $-0.19 | $0.00 | ||
| Q4 24 | $-17.50 | $-0.10 | ||
| Q3 24 | $1.06 | $-0.09 | ||
| Q2 24 | $1.41 | $-0.09 | ||
| Q1 24 | $1.10 | $-0.19 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $4.5B |
| Total DebtLower is stronger | $11.4B | $836.4M |
| Stockholders' EquityBook value | $4.0B | $4.4B |
| Total Assets | $21.7B | $8.2B |
| Debt / EquityLower = less leverage | 2.81× | 0.19× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $4.5B | ||
| Q3 25 | — | $4.0B | ||
| Q2 25 | — | $2.8B | ||
| Q1 25 | — | $2.5B | ||
| Q4 24 | — | $2.6B | ||
| Q3 24 | — | $2.7B | ||
| Q2 24 | — | $2.6B | ||
| Q1 24 | — | $2.8B |
| Q4 25 | $11.4B | $836.4M | ||
| Q3 25 | $11.7B | — | ||
| Q2 25 | $12.7B | — | ||
| Q1 25 | $12.4B | — | ||
| Q4 24 | $11.1B | — | ||
| Q3 24 | $11.3B | — | ||
| Q2 24 | $11.1B | — | ||
| Q1 24 | $11.0B | — |
| Q4 25 | $4.0B | $4.4B | ||
| Q3 25 | $4.0B | $4.1B | ||
| Q2 25 | $5.3B | $3.8B | ||
| Q1 25 | $5.2B | $3.5B | ||
| Q4 24 | $5.2B | $3.3B | ||
| Q3 24 | $7.3B | $3.4B | ||
| Q2 24 | $7.2B | $3.4B | ||
| Q1 24 | $7.1B | $3.4B |
| Q4 25 | $21.7B | $8.2B | ||
| Q3 25 | $22.2B | $7.6B | ||
| Q2 25 | $23.7B | $6.3B | ||
| Q1 25 | $23.2B | $5.8B | ||
| Q4 24 | $22.9B | $5.9B | ||
| Q3 24 | $25.9B | $5.8B | ||
| Q2 24 | $25.8B | $5.7B | ||
| Q1 24 | $26.0B | $5.7B |
| Q4 25 | 2.81× | 0.19× | ||
| Q3 25 | 2.95× | — | ||
| Q2 25 | 2.41× | — | ||
| Q1 25 | 2.39× | — | ||
| Q4 24 | 2.14× | — | ||
| Q3 24 | 1.56× | — | ||
| Q2 24 | 1.54× | — | ||
| Q1 24 | 1.56× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $252.0M | $417.3M |
| Free Cash FlowOCF − Capex | $168.0M | $379.8M |
| FCF MarginFCF / Revenue | 7.6% | 25.4% |
| Capex IntensityCapex / Revenue | 3.8% | 2.5% |
| Cash ConversionOCF / Net Profit | 18.00× | 6.28× |
| TTM Free Cash FlowTrailing 4 quarters | $803.0M | $941.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $252.0M | $417.3M | ||
| Q3 25 | $447.0M | $402.6M | ||
| Q2 25 | $410.0M | $263.6M | ||
| Q1 25 | $37.0M | $44.1M | ||
| Q4 24 | $494.0M | $75.2M | ||
| Q3 24 | $79.0M | $188.4M | ||
| Q2 24 | $292.0M | $-95.6M | ||
| Q1 24 | $101.0M | $-308.6M |
| Q4 25 | $168.0M | $379.8M | ||
| Q3 25 | $383.0M | $354.5M | ||
| Q2 25 | $317.0M | $219.8M | ||
| Q1 25 | $-65.0M | $-12.3M | ||
| Q4 24 | $389.0M | $-17.3M | ||
| Q3 24 | $-9.0M | $54.7M | ||
| Q2 24 | $187.0M | $-205.5M | ||
| Q1 24 | $-36.0M | $-465.1M |
| Q4 25 | 7.6% | 25.4% | ||
| Q3 25 | 15.8% | 25.1% | ||
| Q2 25 | 12.5% | 16.7% | ||
| Q1 25 | -2.7% | -1.1% | ||
| Q4 24 | 16.4% | -1.5% | ||
| Q3 24 | -0.3% | 5.5% | ||
| Q2 24 | 7.1% | -22.1% | ||
| Q1 24 | -1.4% | -61.9% |
| Q4 25 | 3.8% | 2.5% | ||
| Q3 25 | 2.6% | 3.4% | ||
| Q2 25 | 3.7% | 3.3% | ||
| Q1 25 | 4.3% | 5.0% | ||
| Q4 24 | 4.4% | 8.2% | ||
| Q3 24 | 3.3% | 13.3% | ||
| Q2 24 | 4.0% | 11.8% | ||
| Q1 24 | 5.2% | 20.8% |
| Q4 25 | 18.00× | 6.28× | ||
| Q3 25 | — | 3.22× | ||
| Q2 25 | 2.06× | 2.79× | ||
| Q1 25 | — | 34.71× | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.68× | — | ||
| Q2 24 | 1.88× | — | ||
| Q1 24 | 0.83× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CE
| Engineered Materials | $1.3B | 58% |
| Acetyl Chain | $940.0M | 43% |
ONC
Segment breakdown not available.
